Lancet Comment Urges Action on HIV Mortality Gap for Adolescents

Adolescents living with HIV continue to die at higher rates than the general population despite decades of progress in antiretroviral therapy, according to a new comment published in The Lancet. The piece points to a persistent mortality gap that has not closed even as treatment has become more effective and widely available for adults.

The comment cites a stark disparity in access: approximately 60% of adolescents are on antiretroviral therapy, compared with 78% of people overall. For those who do receive the life-saving drugs, inconsistent adherence to daily oral regimens remains a major obstacle. Poor adherence leads to viral non-suppression, which in turn raises the risk of clinical failure and death.

The LATA trial, reported in The Lancet by Mutsa Bwakura-Dangarembizi and colleagues, was conducted in the four African countries where most of the world's 1.57 million adolescents living with HIV reside. The trial offers hope that the adherence challenges of daily oral therapy can be mitigated with longer-acting injectable treatment options.

The comment underscores that while antiretroviral therapy has transformed HIV from a fatal illness into a manageable chronic condition for many, adolescents have not benefited equally. The gap in access and adherence is not merely a matter of numbers; it translates into preventable deaths among a population that should be entering adulthood with the same prospects as their peers.

Daily pill regimens can be particularly difficult for adolescents, who face unique social, psychological, and developmental pressures. Stigma, disclosure concerns, and the transition from pediatric to adult care can all disrupt consistent treatment. The result is a cycle of viral rebound and clinical deterioration that could be avoided with more supportive and simplified treatment approaches.

The LATA trial's focus on long-acting injectables represents a potential shift in how adolescent HIV care is delivered. If such regimens prove effective and acceptable, they could reduce the burden of daily adherence and help close the mortality gap. The comment frames this as a promising step, though it does not suggest that injectables alone will solve the broader access and adherence challenges.

The four African countries where the trial was conducted carry the heaviest burden of adolescent HIV globally. Improvements in treatment delivery there would have a disproportionate impact on global mortality statistics. The comment calls attention to the need for targeted strategies that address the specific barriers adolescents face, rather than assuming that adult-focused approaches will suffice.

While the comment does not provide new primary data, it synthesizes existing evidence to argue that the mortality gap is both persistent and addressable. The authors suggest that longer-acting treatment options, combined with efforts to improve access and adherence support, could meaningfully change outcomes for adolescents living with HIV.

The piece also implicitly raises questions about how health systems track and treat adolescents, a group that often falls between pediatric and adult care. Without dedicated attention, the disparity is likely to endure. The LATA trial results, once fully reported, will be closely watched by clinicians and policymakers seeking to reduce deaths in this vulnerable population.

For now, the comment serves as a reminder that advances in HIV treatment have not reached everyone equally. The 60% access figure for adolescents stands in contrast to the 78% overall rate, and the consequences are measured in lives lost. The hope is that longer-acting injectables and renewed focus on adolescent-specific care can begin to close that gap.